Our perspectives and foresight

PacBio partnered with LINUS to redefine its brand and expand beyond its limited market share. LINUS’s strategy highlighted PacBio’s commitment to innovation and collaboration, appealing to the genomics community’s desire to challenge norms. The rebrand, with a refreshed identity and impactful product launches, positioned PacBio as an accessible leader dedicated to advancing scientific progress.

Twist Bioscience, pioneers of a groundbreaking technology for high-quality synthetic DNA production, set out to challenge an industry long dominated by a single player. Rather than competing on price, Twist identified a strong demand within the pharma and biotech sectors for advanced genome engineering capabilities. By launching a series of value-driven products at premium pricing, Twist aimed to break free from the traditional price wars and redefine the market’s expectations for DNA synthesis.

Charles River Laboratories, known for their extensive preclinical research services, aimed to elevate their reputation to that of a global CRO. Recognizing the fractured nature of pharma/CRO relationships, they sought to redefine what true partnership means by focusing on a shared mission: the patient. Through a series of cinematic films, Charles River showcased their collaborative approach, emphasizing their commitment to working alongside pharma clients for the ultimate benefit of patients.

In the evolving landscape of precision medicine, Personalis sought to enhance its position as a leader in genomics and diagnostics. By developing a new brand strategy that empowers care teams with timely, actionable diagnostics and anticipates potential changes in cancer, Personalis positioned itself as an essential partner in the fight for better patient outcomes and future advancements in precision medicine.